190 related articles for article (PubMed ID: 29769624)
1. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.
Thompson PA; Peterson CB; Strati P; Jorgensen J; Keating MJ; O'Brien SM; Ferrajoli A; Burger JA; Estrov Z; Jain N; Kadia TM; Borthakur G; DiNardo CD; Daver N; Jabbour E; Wierda WG
Leukemia; 2018 Nov; 32(11):2388-2398. PubMed ID: 29769624
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Thompson PA; Srivastava J; Peterson C; Strati P; Jorgensen JL; Hether T; Keating MJ; O'Brien SM; Ferrajoli A; Burger JA; Estrov Z; Jain N; Wierda WG
Blood; 2019 Nov; 134(22):1951-1959. PubMed ID: 31537528
[TBL] [Abstract][Full Text] [Related]
3. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
4. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
[TBL] [Abstract][Full Text] [Related]
5. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
7. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
Strati P; Keating MJ; O'Brien SM; Burger J; Ferrajoli A; Jain N; Tambaro FP; Estrov Z; Jorgensen J; Challagundla P; Faderl SH; Wierda WG
Blood; 2014 Jun; 123(24):3727-32. PubMed ID: 24705492
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R; Dahmani A; Boubaya M; Baseggio L; Campos L; Chatelain B; Debliquis A; Drénou B; Jacob MC; Legac E; Le Garff-Tavernier M; Lhoumeau AC; Quiney C; Robillard N; Ticchioni M; Aanei C; Katsahian S; Delepine R; Vaudaux S; Rouillé V; Béné MC; Dartigeas C; Van Den Neste E; Leprêtre S; Feugier P; Cartron G; Leblond V; Lévy V; Cymbalista F;
Leukemia; 2021 Jun; 35(6):1597-1609. PubMed ID: 32934355
[TBL] [Abstract][Full Text] [Related]
9. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir T; Cairns DA; Bloor A; Allsup D; Cwynarski K; Pettitt A; Paneesha S; Fox CP; Eyre TA; Forconi F; Elmusharaf N; Kennedy B; Gribben J; Pemberton N; Sheehy O; Preston G; Schuh A; Walewska R; Duley L; Howard D; Hockaday A; Jackson S; Greatorex N; Girvan S; Bell S; Brown JM; Webster N; Dalal S; de Tute R; Rawstron A; Patten PEM; Hillmen P;
N Engl J Med; 2024 Jan; 390(4):326-337. PubMed ID: 38078508
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
[TBL] [Abstract][Full Text] [Related]
11. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
[TBL] [Abstract][Full Text] [Related]
13. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
[TBL] [Abstract][Full Text] [Related]
14. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Wang XV; Hanson CA; Tschumper RC; Lesnick CE; Braggio E; Paietta EM; O'Brien S; Barrientos JC; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Erba H; Stone R; Litzow MR; Tallman MS; Shanafelt TD; Kay NE
Blood; 2021 Dec; 138(26):2810-2827. PubMed ID: 34407545
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
16. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
[TBL] [Abstract][Full Text] [Related]
17. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Munir T; Howard DR; McParland L; Pocock C; Rawstron AC; Hockaday A; Varghese A; Hamblin M; Bloor A; Pettitt A; Fegan C; Blundell J; Gribben JG; Phillips D; Hillmen P
Leukemia; 2017 Oct; 31(10):2085-2093. PubMed ID: 28216660
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
20. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]